摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(9-(4-aminobutyl)-1-methyl-9H-pyrido[3,4-b]indol-7-yl)methanesulfonamide | 1342261-11-3

中文名称
——
中文别名
——
英文名称
N-(9-(4-aminobutyl)-1-methyl-9H-pyrido[3,4-b]indol-7-yl)methanesulfonamide
英文别名
N-[9-(4-aminobutyl)-1-methylpyrido[3,4-b]indol-7-yl]methanesulfonamide
N-(9-(4-aminobutyl)-1-methyl-9H-pyrido[3,4-b]indol-7-yl)methanesulfonamide化学式
CAS
1342261-11-3
化学式
C17H22N4O2S
mdl
——
分子量
346.453
InChiKey
RIYODNJHOSJJLJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    24
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    98.4
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    参考文献:
    名称:
    Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors
    摘要:
    Haspin is a serine/threonine kinase that phosphorylates Thr-3 of histone H3 in mitosis that has emerged as a possible cancer therapeutic target. High throughput screening of approximately 140,000 compounds identified the beta-carbolines harmine and harmol as moderately potent haspin kinase inhibitors. Based on information obtained from a structure-activity relationship study previously conducted for an acridine series of haspin inhibitors in conjunction with in silico docking using a recently disclosed crystal structure of the kinase, harmine analogs were designed that resulted in significantly increased haspin kinase inhibitory potency. The harmine derivatives also demonstrated less activity towards DYRK2 compared to the acridine series. In vitro mouse liver microsome stability and kinase profiling of a representative member of the harmine series (42, LDN-211898) are also presented. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.01.028
点击查看最新优质反应信息

文献信息

  • Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
    申请人:Higgins Jonathan
    公开号:US20130231360A1
    公开(公告)日:2013-09-05
    The present disclosure is directed to compounds of Formula (I) which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.
  • [EN] BETA-CARBOLINES AS INHIBITORS OF HASPIN AND DYRK KINASES<br/>[FR] BÊTA-CARBOLINES À TITRE D'INHIBITEURS DE KINASES HASPINE ET DYRK
    申请人:BRIGHAM & WOMENS HOSPITAL
    公开号:WO2011133795A2
    公开(公告)日:2011-10-27
    The present disclosure is directed to compounds of Formula ( I ) which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.
  • Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors
    作者:Gregory D. Cuny、Natalia P. Ulyanova、Debasis Patnaik、Ji-Feng Liu、Xiangjie Lin、Ken Auerbach、Soumya S. Ray、Jun Xian、Marcie A. Glicksman、Ross L. Stein、Jonathan M.G. Higgins
    DOI:10.1016/j.bmcl.2012.01.028
    日期:2012.3
    Haspin is a serine/threonine kinase that phosphorylates Thr-3 of histone H3 in mitosis that has emerged as a possible cancer therapeutic target. High throughput screening of approximately 140,000 compounds identified the beta-carbolines harmine and harmol as moderately potent haspin kinase inhibitors. Based on information obtained from a structure-activity relationship study previously conducted for an acridine series of haspin inhibitors in conjunction with in silico docking using a recently disclosed crystal structure of the kinase, harmine analogs were designed that resulted in significantly increased haspin kinase inhibitory potency. The harmine derivatives also demonstrated less activity towards DYRK2 compared to the acridine series. In vitro mouse liver microsome stability and kinase profiling of a representative member of the harmine series (42, LDN-211898) are also presented. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多